Bradley JD - Lumos Pharma Chief Counsel

Insider

Bradley JD is Chief Counsel of Lumos Pharma
Age 45
Phone512 215 2630
Webhttps://lumos-pharma.com

Lumos Pharma Management Efficiency

The company has return on total asset (ROA) of (0.6964) % which means that it has lost $0.6964 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7283) %, meaning that it created substantial loss on money invested by shareholders. Lumos Pharma's management efficiency ratios could be used to measure how well Lumos Pharma manages its routine affairs as well as how well it operates its assets and liabilities.
Lumos Pharma currently holds 585 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Lumos Pharma has a current ratio of 17.24, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Lumos Pharma's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Andrew MBAShattuck Labs
40
Nik ChetwynErasca Inc
N/A
Mark WalletCentury Therapeutics
N/A
BS CMARChampions Oncology
N/A
Steven RuhlForte Biosciences
68
Brian MDRezolute
50
Kenneth JDCentury Therapeutics
N/A
David MDErasca Inc
41
Osvaldo FloresCentury Therapeutics
61
Abhinav ShuklaShattuck Labs
52
Wei MDErasca Inc
54
Lisa TesvichBonoraErasca Inc
N/A
MD MBARezolute
N/A
Michael DiemCentury Therapeutics
53
LLM JDRezolute
63
CPA MSErasca Inc
55
Jonathan MDErasca Inc
53
Gregory RussottiCentury Therapeutics
58
Erin JDShattuck Labs
44
Maria ManciniChampions Oncology
N/A
Robyn SweinhartRezolute
N/A
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. Lumos Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 32 people. Lumos Pharma (LUMO) is traded on NASDAQ Exchange in USA and employs 30 people.

Management Performance

Lumos Pharma Leadership Team

Elected by the shareholders, the Lumos Pharma's board of directors comprises two types of representatives: Lumos Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lumos. The board's role is to monitor Lumos Pharma's management team and ensure that shareholders' interests are well served. Lumos Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lumos Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Richard Hawkins, CEO Chairman
Lori CPA, CFO Officer
MD BA, Chief Officer
Lisa Miller, Director Relations
John McKew, Chief President
Bradley JD, Chief Counsel
Carl Langren, Consultant
BBA CPA, Chief Officer
MD FAAP, Chief Officer
Alpa Parikh, Senior Management
Eddie MBA, Corporate Controller

Lumos Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lumos Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Lumos Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lumos Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lumos Pharma will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Bristol Myers could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myers when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myers - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.
The correlation of Bristol Myers is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myers moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myers can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Other Consideration for investing in Lumos Stock

If you are still planning to invest in Lumos Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Lumos Pharma's history and understand the potential risks before investing.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Transaction History
View history of all your transactions and understand their impact on performance
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments